Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 1/20 | 0.51 |
| ▸ | ACACA | Q13085 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292941 | 0.91 | PPARA (0.57) | CTSSCTSKPPARAPPARGACACB | |
| SCHEMBL2574963 | 0.86 | CTSS (0.54) | CTSSCTSKPPARAACACBATM | |
| SCHEMBL20439333 | 0.86 | CTSS (0.54) | CTSSCTSKPPARAACACBATM | |
| SCHEMBL2574965 | 0.86 | CTSS (0.54) | CTSSCTSKPPARAACACBATM | |
| SCHEMBL20249540 | 0.84 | KLK5 (0.61) | CTSSCTSKPPARAPPARGATM | |
| SCHEMBL12379280 | 0.83 | ACACB (0.56) | PPARAPPARGACACBACACAATM | |
| SCHEMBL1951343 | 0.83 | CTSK (0.63) | CTSSCTSKATMKLK5S1PR3 | |
| SCHEMBL1095763 | 0.83 | CTSK (0.63) | CTSSCTSKATMKLK5S1PR3 | |
| SCHEMBL1095762 | 0.83 | CTSK (0.63) | CTSSCTSKATMKLK5S1PR3 | |
| SCHEMBL23200772 | 0.81 | PPARA (0.52) | CTSSCTSKPPARAPPARGATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989480-B2 | Aryl amino acid derivatives as inhibitors for treating inflammation | DECODE GENETICS EHF (IS) | 2011-08-02 | — | — | US | disclosed |
| US-7989480-B2 | Aryl amino acid derivatives as inhibitors for treating inflammation | DECODE GENETICS EHF (IS) | 2011-08-02 | — | — | US | disclosed |
| EP-2066800-A2 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS OF LTA4H (LEUKOTRIENE A4 HYDROLASE) FOR TREATING INFLAMMATION | Decode Genetics EHF (IS) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008019306-A2 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS OF LTA4H (LEUKOTRIENE A4 HYDROLASE) FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2008-02-14 | — | — | WO | disclosed |
| US-20080033024-A1 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2008-02-07 | — | — | US | disclosed |
| US-20080033024-A1 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033024-A1 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION | LTA4H, LTB4R2, LTB4R | CTSS 806/4885CTSK 1400/4885PPARA 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.